FBLG · CIK 0001958777 · operating
FibroBiologics is a clinical-stage biotechnology company developing fibroblast-based cell therapies targeting chronic diseases. The company's pipeline includes CYMS101, which has completed Phase 1 testing for multiple sclerosis; CYWC628, which completed preclinical development for wound healing; CybroCell for degenerative disc disease; and CYPS317 for psoriasis. The company also maintains early-stage research programs including CYTER915 for human longevity and TCB190 for certain cancers. As a development-stage company, FibroBiologics has not advanced products to commercialization.
The company operates with a lean structure of 15 full-time employees and is headquartered in Houston, Texas. Incorporated in Delaware in 2021, FibroBiologics is listed on Nasdaq. The company has not generated commercial revenue from approved therapies, as its pipeline remains in preclinical and clinical development phases.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-0.42 | $-0.42 | -23.5% | |
| 2024 | $-0.34 | $-0.34 | +50.0% | |
| 2023 | $-0.68 | $-0.68 | — |